5th NovAliX Conference

Biophysics in Drug Discovery 2018

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

 Boston, USA    June 13-15, 2018

Keynote Speaker (Nobel Prize in Chemistry 2013)

KL01 - From Simulations of Biomolecules to Fighting Diseases

Prof. Martin KARPLUS
Prof. Martin KARPLUS
UNIVERSITY OF STRASBOURG, FRANCE & HARVARD UNIVERSITY, Cambridge, United States
Read more

Session 1: Hot Topics

OC04 - Quantitative Irreversible Tethering (QIT) for Covalent Ligand Discovery

Dr Gregory CRAVEN
Dr Gregory CRAVEN
IMPERIAL COLLEGE LONDON, London, United Kingdom
Read more

OC05 - Large Protein Conformational Changes in Pi3kgamma Linked to the Binding of a New Class of Highly Selective Inhibitors

Dr Göran DAHL
Dr Göran DAHL
ASTRAZENECA, Mölndal, Sweden
Read more

OC01 - Making Off-Rate Screening in FBDD More Amenable For Fast Dissociating Compounds

Dr Menachem GUNZBURG
Dr Menachem GUNZBURG
MONASH UNIVERSITY, Parkville, Australia
Read more

OC02 - Novel Active Site and Allosteric Site Binders Identified for FPPS Of T. cruzi

Ms Joy PETRICK
Ms Joy PETRICK
NOVARTIS, Basel, Switzerland
Read more

OC03 - Dynamic Single-Molecule Approaches to Accelerate the Development of More Efficient Drugs

Dr Gerrit SITTERS
Dr Gerrit SITTERS
LUMICKS, Amsterdam, The Netherlands
Read more

IL01 - Binding Kinetics and Thermodynamics in Drug Discovery

Dr Chaohong SUN
Dr Chaohong SUN
ABBVIE, North Chicago, United States
Read more

Session 2: Target Engagement

OC06 - Quantification of Target Occupancy in Cells and Tumor Tissue Using FCCS

Dr Frank BECKER
Dr Frank BECKER
INTANA BIOSCIENCE GMBH, Planegg, Germany
Read more

IL03 - How to Be Selectively Promiscuous

Prof. Jack TAUNTON
Prof. Jack TAUNTON
UNIVERSITY OF CALIFORNIA, San Francisco, United States

IL02 - Chemical Probes for Epigenetic Targets

Prof. Masoud VEDADI
Prof. Masoud VEDADI
STRUCTURAL GENOMICS CONSORTIUM, Toronto, Canada
Read more

Session 3: Cryo-EM (Special Feature of the Conference)

IL05 - Cryo-EM for Characterization and Structure Based Drug Design

Dr Bridget CARRAGHER
Dr Bridget CARRAGHER
NEW YORK STRUCTURAL BIOLOGY CENTER, New York, United States
Read more

IL04 - How Low Can You Go? Size and Resolution Limits Using Conventional Cryo-EM

Dr Gabriel LANDER
Dr Gabriel LANDER
THE SCRIPPS RESEARCH INSTITUTE, San Diego, United States
Read more

OC08 - Strength of Cryo-EM in Drug Discovery: One Could Always See Something

Dr Wen-ti LIU
Dr Wen-ti LIU
NOVALIX, Illkirch, France
Read more

OC07 - Cryo-EM to Address Intractable Targets in Drug Discovery

Dr Hervé REMIGY
Dr Hervé REMIGY
THERMO FISHER SCIENTIFIC, Eindhoven, The Netherlands

IL06 - Single Particle Cryo-EM Structure of the Insulin Receptor:Insulin Complex

Dr Giovanna SCAPIN
Dr Giovanna SCAPIN
MERCK & CO. INC (MSD), Whitehouse Station, United States
Read more

Session 4: Membrane Proteins

IL08 - Structural Insight into Allosteric Modulation of GPCRs

Dr Miles CONGREVE
Dr Miles CONGREVE
HEPTARES, Welwyn Garden City, United Kingdom
Read more

IL07 - New Tools Reveal Mechanisms of Allosteric Coupling in Human GPCRs

Dr Matthew EDDY
Dr Matthew EDDY
UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, United States
Read more

OC10 - Crystal Structures of Human Glycine Receptor Alpha3 Bound to a Novel Class of Analgesic Potentiators

Dr Xin HUANG
Dr Xin HUANG
AMGEN, Cambridge, United States
Read more

OC09 - Enabling NMR-Based Fragment Screening Using Stabilized Native GPCR: Case Study of Adenosine Receptor

Dr Anass JAWHARI
Dr Anass JAWHARI
CALIXAR, Lyon, France
Read more

Session 5: Protein-Protein Interactions

OC11 - Use of Complementary Biophysical Methods to Characterize Ligand Binding to IL-17A

Dr Parag SAHASRABUDHE
Dr Parag SAHASRABUDHE
PFIZER, Groton, United States

OC12 - Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of α-Synuclein Aggregation in Parkinson’s Disease

Ms Roxine STAATS
Ms Roxine STAATS
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

IL09 - Design Considerations for Synthetic Macrocycles in Drug Discovery

Prof. Adrian WHITTY
Prof. Adrian WHITTY
BOSTON UNIVERSITY, Boston, United States
Read more

IL10 - Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction

Dr Shilin XU
Dr Shilin XU
UNIVERSITY OF MICHIGAN, Michigan, United States
Read more

Session 6: Biotherapeutics

IL13 - Emerging Higher Order Structure Techniques in Biotherapeutics Development

Dr Tapan K. DAS
Dr Tapan K. DAS
BRISTOL-MYERS SQUIBB, New York, United States
Read more

IL12 - Multi-Specific Designer Proteins for Tumor Therapeutics

Dr Karyn T. O'NEIL
Dr Karyn T. O'NEIL
ARō BIOTHERAPEUTICS, Philadelphia, United States
Read more

IL11 - Attacking the Cancer Cell Surface-ome with Recombinant Antibodies

Prof. Jim WELLS
Prof. Jim WELLS
UCSF, San Francisco, United States
Read more